The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - McKesson; Myriad Genetics
Research Funding - Myriad Genetics (Inst)
Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults.
 
Erin Frances Cobain
No Relationships to Disclose
 
Dan R. Robinson
No Relationships to Disclose
 
Yi-Mi Wu
No Relationships to Disclose
 
Jessica Everett
No Relationships to Disclose
 
Erica Rabban
No Relationships to Disclose
 
Chandan Kumar
No Relationships to Disclose
 
Scott Schuetze
Honoraria - EMD Serono; EMD Serono; Janssen Research & Development
Consulting or Advisory Role - EMD Serono; EMD Serono; Janssen Research & Development
Research Funding - AB Science (Inst); Amgen (Inst); BioMed Valley Discoveries (Inst); CytRx Corporation (Inst); Janssen Research & Development (Inst); Lilly (Inst); Plexxikon (Inst); Threshold Pharmaceuticals (Inst); ZIOPHARM Oncology (Inst)
 
Ajjai Shivaram Alva
Consulting or Advisory Role - AstraZeneca; Eisai; Roche
Speakers' Bureau - AstraZeneca
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst)
 
Rashmi Chugh
Stock and Other Ownership Interests - Portola Pharmaceuticals
Research Funding - AADi (Inst); Biomarin (Inst); Epizyme (Inst); Lilly (Inst); MabVax (Inst); Morphotek (Inst); Novartis (Inst)
 
Francis P. Worden
Honoraria - Bayer
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme; Merck
 
Mark Zalupski
Research Funding - Halozyme; Newlink Genetics/Pharmatech; Oncomed
 
Scott A. Tomlins
Leadership - Strata Oncology
Stock and Other Ownership Interests - Strata Oncology
Consulting or Advisory Role - Abbvie; Astellas Medivation; Janssen; Roche; Sanofi; Strata Oncology; Ventana Medical Systems
Research Funding - Astellas Medivation (Inst); Compendia Bioscience (Inst); GenomeDx (Inst); Life Technologies (Inst); Thermo Fisher Scientific (Inst)
Patents, Royalties, Other Intellectual Property - I am a coauthor on a patent issued to the University of Michigan on ETS gene fusions in prostate cancer. The diagnostic field of use has been licensed to Hologic/Gen-Probe Inc., who has sublicensed some rights to Ventana Medical Systems/Roche.
Travel, Accommodations, Expenses - Compendia Bioscience; Life Technologies; Strata Oncology; Thermo Fisher Scientific
 
Nithya Ramnath
No Relationships to Disclose
 
Anne F. Schott
Research Funding - Dompé Farmaceutici (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Contributor of 2 "cards" on breast cancer topics to UpToDate; Systems and Methods for Tissue Imaging, 8,185,186, Inventor, Submitted on 04/2008. This is a patent for use of diffusion MRI technology to quantitate response to neoadjuvant breast cancer therapy.
 
Elena Martinez Stoffel
No Relationships to Disclose
 
David C. Smith
Research Funding - Agensys (Inst); Atterocor (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); ImClone Systems (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Millennium (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Regeneron (Inst); Seagen (Inst); Takeda (Inst); Tekmira (Inst); Teva (Inst)
 
Lakshmi Priya Kunju
No Relationships to Disclose
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - Lilly
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Lilly (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Janssen Diagnostics
 
Moshe Talpaz
Consulting or Advisory Role - ARIAD; Novartis; Pfizer
Research Funding - ARIAD (Inst); Incyte (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Arul M. Chinnaiyan
Consulting or Advisory Role - Tempus